Purpose: To report a series of patients with periocular microcystic adnexal carcinoma (MAC) treated with Mohs’ micrographic surgery (MMS). Design: Prospective, interventional case series. Methods: This series included all patients treated with MMS for periocular MAC, who were monitored by the Skin and Cancer Foundation Australia between 1993 and 2002. Results: There were 5 patients (4 males, 1 female) with a mean age of 52 ± 12 years. Four tumors were located in the medial canthus and one in the lower lid.The tumor was initially misdiagnosed as basal cell carcinoma in 3 patients and squamous cell carcinoma in 1 patient. The average number of excision levels required for complete removal of the tumor during MMS was 2.2 (range 1–6). Perineural invasion was recorded in one patient.Five-year follow-up data was available for 3 patients, and there was no tumor recurrence in any of these cases. Conclusion: The low 5-year recurrence rate of periocular MAC with MMS emphasizes the importance of margin-controlled excision of this tumor.

Goldstein DJ, Barr RJ, Cruz DJ: Microcystic adnexal carcinoma: a distinct clinicopathologic entity. Cancer 1982;50:566–572.
Lipper S, Peiper SC: Sweat gland carcinoma with syringomatous features: a light microscopic and ultrastructural study. Cancer 1979;44:157–163.
Cooper PH, Mills SE: Microcystic adnexal carcinoma. J Am Acad Dermatol 1984;10:908–914.
Cooper PH, Mills SE, Leonard DD, Santa Cruz DJ, Headington JT, Barr RJ, Katz DA: Sclerosing sweat duct (syringomatous) carcinoma. Am J Surg Pathol 1985;9:422–433.
Cooper PH: Sclerosing carcinomas of sweat ducts (microcystic adnexal carcinoma). Arch Dermatol 1986;122:261–264.
Santa Cruz DJ: Sweat gland carcinomas: a comprehensive review. Semin Diagn Pathol 1987;4:38–74.
Requena L, Marquina A, Alegre V, Aliaga A, Sanchez Yus E: Sclerosing (microcystic adnexal) carcinoma: a tumour from a single eccrine origin. Clin Exp Dermatol 1990;15:222–224.
Sebastien TS, Nelson BR, Lowe L, Baker S, Johnson TM: Microcystic adnexal carcinoma. J Am Acad Dermatol 1993;29:840–845.
Salerno S, Terrill P: Will MAC be back? ANJ J Surg 2003;73:830–832.
Burns MK, Chen SP, Goldberg LH: Microcystic adnexal carcinoma: ten cases treated by Mohs’ micrographic surgery. J Dermatol Surg Oncol 1994;20:429–434.
Friedman PM, Friedman RH, Jiang B, Nouri K, Amonette R, Robins P: Microcystic adnexal carcinoma: collaborative series review and update. J Am Acad Dermatol 1999;41:225–231.
Chiller K, Passaro D, Scheuller M, Singer M, McCalmont T, Grekin RC: Microcystic Adnexal carcinoma: Forty eight cases, their treatment and their outcome. Arch Dermatol 2000;136:1355–1359.
Snow S, Madjar DD Jr, Hardy S, Bentz M, Lucarelli MJ, Bechard R, Aughenbaugh W: Microcystic adnexal carcinoma: report of 13 cases and review of the literature. Dermatol Surg 2001;27:401–408.
Abbate M, Zeitouni N, Seyler M, Hicks W, Loree T, Cheney RT: Clinical course, risk factors and treatment of microcystic adnexal carcinoma: a short series report. Dermatol Surg 2003;29:1035–1038.
Hoppenreijs VP, Reuser TT, Mooy CM, de Keizer RJ, Mouritis MP: Syringomatous carcinoma of the eyelid and orbit: a clinical and histopathological challenge. Br J Ophthalmol 1997;81:668–672.
Duffy MT, Harrison W, Sassoon J, Hornblass A: Sclerosing sweat duct carcinoma of the eyelid margin: unusual presentation of a rare tumor. Ophthalmology 1999;106:751–756.
Hesse RJ, Scharfenberg JC, Ratz JL, Grierner E: Eyelid microcystic adnexal carcinoma. Arch Ophthalmol 1995;113;494–496.
Hunts JH, Patel BCK, Langer PD, Anderson RL, Gerwels JW: Microcystic adnexal carcinoma of the eyebrow and eyelid. Arch Ophthalmol 1995;113:1332–1333.
Clement CI, Genge J, O’Donnell BA, Lochhead AG: Orbital and periorbital microcystic adnexal carcinoma. Ophthal Plast Reconstr Surg 2005;21:97–102.
Leibovitch I, Huilgol SC, Selva D, Lun K, Richards S, Paver R: Microcystic adnexal carcinoma: treatment with Mohs’ micrographic surgery. J Am Acad Dermatol 2005;52:295–300.
McAlvany JP, Stonecipher MR, Leshin B, Richard E, White W: Sclerosing sweat duct carcinoma in an 11-year-old boy. J Dermatol Surg Oncol 1994;20:767–768.
Glatt HJ, Proia AD, Tsoy EA, Fetter BF, Klintworth GK, Neuhaus R, Font RL: Malignant syringoma of the eyelid. Ophthalmology 1984;91:987–990.
Ongenae KC, Verhaegh MEJM, Vermeulen AHM, Naeyaert JM: Microcystic adnexal carcinoma: an uncommon tumor with debatable origin. Dermatol surg 2002;27:979–984.
Wick MR, Cooper PH, Swanson PE, Kaye VN, Sun TT: Microcystic adnexal carcinoma: an immunohistochemical comparison with other cutaneous appendage tumors. Arch Dermatol 1990;126:189–194.
Leboit PE, Sexton M: Microcystic adnexal carcinoma of the skin. J Am Acad Dermatol 1993;29:609–618.
Mayer MH, Winton GB, Smith AC, Lupton GP, Parry EL, Shagets FW: Microcystic adnexal carcinoma (sclerosing sweat duct carcinoma). Plast Reconstr Surg 1989;84:970–975.
Rapini RP: Comparison of methods for checking surgical margins. J Am Acad Dermatol 1990;23:288–294.
Feasel AM, Brown TJ, Bogle MA, Tschen JA, Nelson BR: Perineural invasion of cutaneous malignancies. Dermatol Surg 2001;27:531–542.
Mendenhall WM, Amdur RJ, Williams LS, Mancuso AA, Stringer SP, Mendenhall NP: Carcinoma of the skin of the head and neck with perineural invasion. Head Neck 2002;24:78–83.
McCord MW, Mendenhall WM, Parsons JT, Amdur RJ, Stringer SP, Cassisi NJ, Million RR: Skin cancer of the head and neck with clinical perineural invasion. Int J Radiat Oncol Biol Phys 2000;47:89–93.
Matorin PA, Wagner RF Jr: Mohs’ micrographic surgery: technical difficulties posed by perineural invasion. Inter J Dermatol 2002;31:83–86.
Marshall J, Mortimore R, Sullivan T: Sclerosing sweat duct carcinoma of the orbit. Orbit 2003;22:165–170.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.